Differentiated thyroid carcinoma - How to improve the long-term results? Twenty-five-year outcomes of 850 patients;Cancers thyroïdiens différenciés: Comment optimiser les résultats à long terme? À propos des résultats à 25 ans d'une série de 850 opérés

Bulletin de l'Academie Nationale de Medecine

Volumn 190, Issue 1, 2006, Pages 89-109

  Melliere, Didier ^a   Hindie, Elif ^b   Becquemin, Jean Pierre ^a   Desgranges, Pascal ^a   Allaire, Eric ^a   Geachan, Emile ^c   Rouëssé, Jacques ^d   Jaffiol, Claude ^d   Nezelof, Christian ^d   Chapuis, Yves ^d   Larcan, Alain ^d   Mornex, René ^d   Jeanteur, Philippe ^d  

^a HENRI MONDOR HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c Unité de Recherches Mesures Physiques Métrologie   (France)

^d NONE

Author keywords

Thyroid diseases classification; Thyroid diseases radiotherapy; Thyroid diseases surgery; Thyroid diseases therapy

Indexed keywords

EID: 33745775455     PISSN: 00014079     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0001-4079(19)33383-7     Document Type: Article

References (48)

1. TUBIANA M. - Le cancer du corps thyroïde. Evolution à long terme. Traitement et Recherches physiopathologiques. Rev. Franç. Endocrinol. Clin. 1980, 21, 103-23.
2. BLONDEAU P. - Le cancer thyroïdien est-il grave? Etude pronostique de 800 cancers opérés dont 143 cancers nodulaires différenciés suivis plus de vingt ans. Bull Acad. Natl. Méd., 1992, 176, 1087-1096.
3. MAZZAFERRI E.L., KLOOS R.T. - Current approaches to primary therapy for papillary and follicular thyroid cancers. J. Clin. Endocrinol. Metab., 2001, 86, 1047-63.
4. ANDEM - La prise en charge diagnostique du nodule thyroïdien. Recommandations pour la pratique clinique. (ANDEM édit. Paris), 1997.
5. SCHLUMBERGER M., PACINI F. - Tumeurs de la thyroïde. (Nucleon édit. Paris) 1997.
6. MODIGLIANI E., COHEN R., LEGRAND M. - Pathologie thyroïdienne en pratique courante. (Doin édit. Paris) 1998.
7. MELLIERE D. - Que faire devant la récidive de nodule(s) thyroïdien(s) chez un patient préalablement opéré de goitre bénin? In Entretiens de Bichat-2003 volume «Chirurgie et Spécialités», Expansion Scientifique édit. (Paris) 2003.
8. VAN DE VELDE C.I.H, HAMMING J.F., GOSLING B.M. et al. - Report of the consensus development conference on the management of differentiated thyroid cancer in the Neerlands. Eur. J. Clin. Oncol., 1988, 24, 287-92.
9. SINGER P.A., COOPER D.S., DANIELS G.H. et al. - Treatment guidelines for patients with thyroid nodules and well-differentiated cancer. Arch. Inter. Med. 1996, 156, 2165-72.
10. GRANT C.S., HAY I.D., GOUGH I.R. et al. - Local recurrence in papillary thyroid carcinoma: is extent of surgical resction important? Surgery 1988, 104, 954-62.
11. SAMAAN N.A., SCHULTZ P.N., HICKEY R.C. et al. - The results of various modalities of treatment of well differentiated carcinoma: a retrospective review of 1599 patients. JCE & M 1992, 75, 714-20.
12. HAY I.D., CONAHEY W.M., GOELLNER J.M. - Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2512 consecutive patients during 1940 through 2000. Trans. Am. Clin. Climatol. Assoc., 2002, 113, 241-61.
13. DE VATHAIRE F., SCHLUMBERGER M., DELISLE M.J. et al. - Leukemias and cancers following Iodine 131 administration for thyroid cancer. Br. J. Cancer., 1997, 75, 734-9.
14. ROBBINS R.J., SCLUMBERGER M.J. - The evolving role of (131)I for the treatment of differentiated thyroid carcinoma. J. Nucl. Med., 2005, 46 Suppl. 1, 28S-37S. Review.
15. PUJOL P., DAURES J.P., NSALAKA N., BALDET L., BRINGER J., JAFFIOL C. - Degree of thyroid suppression as a prognostic determinant in differentiated thyroid carcinoma. J Clin Endocrinol Metab 1996, 81, 4318, 24.
16. SCHLUMBERGER M., FRAGU P., TRAVAGLI J.P. et coll. -Intérêt du dosage de la thyroglobuline sérique dans le cancer de la thyroïde. Nouv. Presse Med., 1982, 11, 3101-5.
17. CAILLEUX A.F., BAUDIN E., TRAVAGLI J.P. et al. - Is diagnostic Iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer. J. Clin. Endocrinol. Metab., 2000, 85, 175-8.
18. PACINI F., CAPEZZONE M., ELISEI R., CECCARELLI C., TADDEI D., PINCHERA A. - Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J. Clin. Endocrinol. Metab. 2002, 87, 1499-501.
19. PACINI F., MOLINARO E., CASTAGNETA M. et al. - Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab., 2003, 88, 3668-73.
20. MAZZAFERRI E.L., ROBBINS R.J., SPENCER C.A. et al. - A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J. Clin. Endocrinol. Metabol., 2003, 88, 1433-41.
21. SCHLUMBERGER M., BEG G., COHEN O. et al. - Follow up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur. J. Endocrin., 2004, 150, 105-12.
22. RONGA G., FIORENTINO A., PASERIO et al. - Can Iodine-131 Whole-Body Scan be replaced by Thyroglobuline measurement in the post-surgical follow-up of differentiated carcinoma? J. Nuclear Med., 1990, 31, 1766-73.
23. MAZZAFERRI E.L., KLOOS R.T. - Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J. Clin. Endocrinol. Metab., 2002, 87, 1490-8.
24. BACHELOT A., LEBOULLEUX S., BAUDINE et al. - Neck recurrence from thyroid carcinoma: serum thyroglobulin and high-dose total body scan are not reliable criteria for cure after radioiodine treatment. Clin. Endocrinol., (Oxf). 2005, 62, 376-9.
25. GRANT S., LUTTREL B., REEVE T. et al. - Thyroglobulin may be undetectable in the serum of patients with metastatic disease secondary to differentiated thyroid carcinoma. Follow-up of differentiated thyroid carcinoma. Cancer, 1984, 54, 1625-8.
26. WESTBURY C., VINI L., FISCHER C., HARMER C. - Recurrent differentiated thyroid cancer without elevation of serum thyroglobulin. Thyroid, 2000, 10, 171-6.
27. BREDEL A.J., LAMBERT B., GUYOT M. et al. - Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow up of differentiated thyroid carcinoma. Eur. J. Nucl. Med., 1990, 16, 35-8.
28. OZATA M., SUZUKI S., MIYAMOTO T., LIU R.T., FIERRO-RENOY F., DE GROOT L.J. - Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J. Clin. Endocrinol. Metab., 1994, 79, 98-105.
29. MELLIERE D., BERRAHAL D., HINDIE E., BECQUEMIN J.P., LANGE F. - Cancers thyroïdiens différenciés. Résultats à 20 ans d'un protocole fondé sur des critères pronostiques simples. Presse Méd. (Paris) 1997, 26, 1276-83.
30. MAZZAFERRI E.L., JHIANG S.M. - Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid carcinoma. Amer. J. Med. 1994, 97, 418-27.
31. th edition. (Wiley-Liss, New York 2002) pp. 52-56.
32. D'AVANZO A., ITUARTE P., TRESELER P. et al. - Prognostic scoring systems in patients with follicular thyroid cancer: a comparison of different staging systems in predicting the patient outcome. Thyroid, 2004, 14, 453-8.
33. th Edition TNM classification system in a retrospective analysis of 169 patients. Thyroid 2004, 14, 65-70.
34. VAN NGUYEN K., DILAWARI R.A. - Predictive value of AMES scoring system in selection of extent of surgery in well differentiated carcinoma of thyroid. Am. Surg. 1995, 61, 151-5.
35. PROYE C., GONTIER A., CAPUANO G. et coll. - Persistance et récidives loco-régionales des cancers thyroïdiens différenciés opérés. 22 cas sur 589 patients traités de 1964 à 1990, suivis de 5 à 31 ans. Ann. Endocrinol. (Paris), 1997, 58, 233-9.
36. HAY I.D., GRANT C.S., VAN HEERDEN J.A., GOELLNER J.R., EBERSOLD J.R., BERGSTRAHL E.J. - Papillary Thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery, 1993, 112, 1139-47.
37. PACINI F, ELISEI R., CAPEZZONE M. et al. - Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients. Thyroid. 2001, 11, 877-81.
38. HAY I.D., GRANT C.S., BEGSTRAHL E.J., THOMPSON G.B., VAN HEERDEN J.A., GOELLNER J.R. - Unilateral total lobectomy: Is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery, 1998, 124, 958-66.
39. ALEXANDER C., BADER J.B., SCHAEFER A., FINKE C., KIRSCH C.M. - Intermediate and long-term effects of high-dose radioiodine therapy for thyroid carcinoma. J. Nucl. Med., 1998, 39, 1551-54.
40. DELISLE M.J., CLERC J. - L'iode 131 lors du traitement initial du cancer thyroïdien. Ann. Endocrinol. (Paris) 1997, 58, 197-203.
41. KEH-CHUAN L., GREENSPAN F.S., GEE L., MILLER T., YEO P. - Pathological Tumor- node metastasis (pTNM) staging for papillary and follicular thyroid cacinomas: a retrospective analysis of 700 patients. J. Clin. Endocrinol. Metab., 1997, 52, 3555-62.
42. HINDIE E., MELLIERE D., LANGE F. et al. - Functionning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis? Eur. J. Nucl. Med. Mol. Imaging, 2003, 30, 974-81.
43. PACINI F., SCHLUMBERGER M., HARMER C. et al. Post-chirurgical use of radioiodine in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrin, 2005, 153, 651-9.
44. PROYE C., DROMER D., CARNAILLE B. - Is it worthwhile to treat bone metastasis from differentiated carcinoma with radioactive iodine? World J. Surg. 1992, 16, 640-6.
45. GRUNWALD F., PAKOS E., BENDER H. et al. - Redifferenciation therapy with retinoic acid in follicular thyroid cancer. J. Nucl. Med., 1998, 39, 1555-8.
46. PINEDA J.D., LEE T., AIN K., REYNOLDS J.C., ROBBINS J. - Iodine 131 therapy for thyroid cancer patients with elevated thyroglobuline and negative diagnostic scan. J. Clin. Endocrino. Metab., 1955, 80, 1488-92.
47. PACE I., KLAIN M., ALBANESE C. et al. Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment. Eur. J. Nuclear Med. and Mol. Imag., 2006, 33, 179-83.
48. HELAL B.O., MERLET P., TOUBERT M.E. et al. - Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J. Nucl. Med., 2001, 42, 1464-9.